sprite-preloader
Anzeige
Mehr »
Freitag, 23.02.2018 Börsentäglich über 12.000 News von 579 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
15.02.2018 | 16:01
(3 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

DUBLIN, Feb. 15, 2018 /PRNewswire/ --

The "Disease Analysis: Head and Neck Cancer" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Head and neck cancer is the sixth most common cancer worldwide, and includes malignancies that can originate in the oral cavity, salivary glands, sinuses, and throat. Around 90% of cases have an epithelial origin, which present as squamous cell carcinomas. Environmental factors such as tobacco smoking and alcohol consumption greatly increase the risk of developing head and neck cancers. If diagnosed at an early stage, treatment for these cancers can be curative; however, the majority of patients are diagnosed when the disease is advanced, resulting in the need for more than one treatment modality.

Market Snapshot

  • The head and neck cancer market is projected to reach $2.8bn in value by 2026, with growth driven by immunotherapies.
  • Erbitux continues to be the primary targeted therapy prescribed for the treatment of advanced head and neck cancer.
  • The incident population of this common cancer is predicted to increase over the forecast period of 2016-36.
  • Erbitux's position as the leading targeted therapy for SCCHN is being challenged as immunotherapies enter the market.
  • Immunotherapy developers will look to minimize direct competition in SCCHN by targeting new patient settings.

Key Topics Covered:

Forecast: Head And Neck Cancer (Published On 01 December 2017)

  • Executive Summary
  • Recent Forecast Updates
  • Market Dynamics
  • Forecast And Future Trends
  • Market Definition And Methodology
  • Primary Research Methodology
  • Product Profile (Late Stage): Bavencio
  • Product Profile: Erbitux
  • Product Profile (Late Stage): Gilotrif
  • Product Profile (Late Stage): Imfinzi
  • Product Profile: Keytruda
  • Product Profile (Late Stage): Multikine
  • Product Profile: Opdivo

Treatment: Head And Neck Cancer (Published On 15 September 2017)

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

Epidemiology: Head And Neck Cancer (Published On 08 August 2017)

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths And Limitations
  • Bibliography
  • Appendix: Additional Sources

Marketed Drugs: Head And Neck Cancer (Published On 01 December 2017)

  • Executive Summary
  • Product Overview
  • Product Profile: Erbitux
  • Product Profile: Keytruda
  • Product Profile: Opdivo

Pipeline: Head And Neck Cancer (Published On 01 December 2017)

  • Executive Summary
  • Clinical Pipeline Overview
  • Product Profile (Late Stage): Bavencio
  • Product Profile (Late Stage): Gilotrif
  • Product Profile (Late Stage): Imfinzi
  • Product Profile (Late Stage): Multikine

For more information about this report visit https://www.researchandmarkets.com/research/z49sf7/global_head_and?w=5

Media Contact:


Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


© 2018 PR Newswire